Iambic Submits IND for a Potentially Brain-Penetrant KIF18A Inhibitor IAM217, Its Second Wholly Owned AI-Discovered Candidate
Iambic official newsroom · 行業原文收錄 · 來源發佈：Mon Oct 05 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收錄：Thu Oct 08 2026 09:07:58 GMT+0000 (Coordinated Universal Time)
已保存的原文節選
In nonclinical studies, IAM217 was observed to have potent and selective target engagement with a favorable drug-drug interaction profile IAM217 is believed to be brain penetrant, producing regression of established intracranial tumors in a preclinical model IAM217 was designed using Iambic's molecular superintelligence platform which included structural enablement using NeuralPLexer and without a
以上為帶出處的原文節選，完整內容請閱讀原始鏈接。自動收錄與主題分類不等於事實核驗。